Two lung cancer drugs approved and one rejected for NHS Scotland
An immunotherapy and a targeted treatment have been recommended for use on the NHS in Scotland, but a third treatment was rejected. The Scottish Medical Consortium (SMC) approved the use of two new treatment options—dacomitinib (Vizimpro) and pembrolizumab (Keytruda) – for some patients with non small cell lung cancer. But a third lung cancer drug, osimertinib, has been rejected by […]
Read more